Nitroglycerine and sodium trioxodinitrate: From the discovery to the preconditioning effect

Journal of Cardiovascular Medicine

Volumn 14, Issue 10, 2013, Pages 698-704

  Pagliaro, Pasquale ^a   Gattullo, Donatella ^a   Penna, Claudia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Angeli's salt; Cardioprotection; Nitric oxide; Nitroglycerine; Nitroxyl

Indexed keywords

ATORVASTATIN; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; NICORANDIL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PENTAERYTHRITYL TETRANITRATE; REACTIVE OXYGEN METABOLITE; SODIUM TRIOXODINITRATE; TELMISARTAN; UNCLASSIFIED DRUG;

BLOOD VESSEL REACTIVITY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; REVIEW; STABLE ANGINA PECTORIS; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRITES; NITROGLYCERIN; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 84885418397     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283621ac6     Document Type: Review

References (75)

1. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 2000; 27:313-319.
2. Goodman LS, Gilman A. The pharmacological basis of therapeutics. 2nd ed. New York: Macmillan; 1955; p. 730.
3. Brunton TL. Use of nitrite of amyl in angina pectoris. Lancet 1867; ii:97- 98.
4. Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res 1999; 43:572-579.
5. Luca MC, Liuni A, Muxel S, et al. Chronic pharmacological preconditioning against ischemia. Clin Hemorheol Microcirc 2011; 49:287-293.
6. Lisi M, Oelze M, Dragoni S, et al. Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates. Clin Res Cardiol 2012; 101:453-459.
7. Yao SK, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992; 86:1302-1309.
8. Recchia FA, McConnell PI, Loke KE, et al. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 1999; 44:325- 332.
9. Heusch G, Post H, Michel MC, et al. Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 2000; 87:146-152.
10. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 2004; 61:402-413.
11. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 18:739-749.
12. Gruhn N, Boesgaard S, Eiberg J, et al. Effects of large conductance Ca(2)-activated K() channels on nitroglycerin-mediated vasorelaxation in humans. Eur J Pharmacol 2002; 446:145-150.
13. Pagliaro P. Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. Life Sci 2003; 73:2137-2149.
14. Kleschyov AL, Oelze M, Daiber A, et al. Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res 2003; 93:e104-e112.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
16. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
17. Furchgott RF. An historical survey and prospects of research on EDRF. Nihon Heikatsukin Gakkai Zasshi 1987; 23:435-440.
18. Zweier JL, Samouilov A, Kuppusamy P. Nonenzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta 1999; 1411:250- 262.
19. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001; 33:1897-1918.
20. Martin C, Schulz R, Post H, et al. Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia. Cardiovasc Res 2007; 74:46-55.
21. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 2011; 14:833-850.
22. Penna C, Perrelli MG, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal 2013; 18:556-599.
23. Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103:2935-2941.
24. Crisafulli A, Melis F, Tocco F, et al. Exercise-induced and nitroglycerininduced myocardial preconditioning improves hemodynamics in patients with angina. Am J Physiol Heart Circ Physiol 2004; 287:H235-H242.
25. Heusch G. Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 2001; 103:2876- 2878.
26. Pagliaro P, Mancardi D, Rastaldo R, et al. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 2003; 34:33-43.
27. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124- 1136.
28. Abete P, Ferrara N, Cacciatore F, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997; 30:947-954.
29. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009; 83:247-261.
30. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation 1999; 100:559-563.
31. Abete P, Cacciatore F, Testa G, et al. Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev 2010; 9:153-162.
32. Ambrosio G, Del Pinto M, Tritto I, et al., GRACE Investigators. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52, 693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010; 31:430-438.
33. Battipaglia I, Scalone G, Milo M, Di Franco A, Lanza GA, Crea F. Upper arm intermittent ischaemia reduces exercise-related increase of platelet reactivity in patients with obstructive coronary artery disease. Heart 2011; 97:1298-1303.
34. Crisafulli A, Melis F, Tocco F, et al. Delayed preconditioning-mimetic actions of exercise or nitroglycerin do not affect haemodynamics and exercise performance in trained or sedentary individuals. J Sports Sci 2007; 25:1393-1401.
35. Niccoli G, Altamura L, Fabretti A, et al. Ethanol abolishes ischemic preconditioning in humans. J Am Coll Cardiol 2008; 51:271-275.
36. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood) 2011; 236:390-401.
37. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med 2008; 12:435-458.
38. Penna C, Mancardi D, Rastaldo R, Pagliaro P. Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta 2009; 1787:781-793.
39. Nakano A, Liu GS, Heusch G, et al. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 2000; 32:1159-1167.
40. Banerjee S, Tang X-L, Qiu Y, et al. Nitroglycerin induces late preconditioning against myocardial stunning via a PKC-dependent pathway. Am J Physiol 1999; 277:H2488-H2494.
41. Shinmura K, Xuan YT, Tang XL, et al. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 2002; 90:602-608.
42. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104:189-202.
43. Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 2004; 109:1714-1717.
44. Gori T, Di Stolfo G, Sicuro S, et al. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol 2007; 64:145-150.
45. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118:1915-1919.
46. Li Q, Guo Y, Wu WJ, et al. Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 2011; 106:1355- 1366.
47. Obal D, Dai S, Keith R, et al. Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion. Basic Res Cardiol 2012; 107:305-318.
48. Guo Y, Sanganalmath SK, Wu W, et al. Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol 2012; 107:253-260.
49. Post H, Schulz R, Behrends M, et al. No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine. J Mol Cell Cardiol 2000; 32:725-733.
50. Bolli R, Dawn B, Tang XL, et al. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 1998; 93:325-338.
51. Rassaf T, Poll LW, Brouzos P, et al. Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J 2006; 27:1699-1705.
52. Oppermann M, Suvorava T, Freudenberger T, et al. Regulation of vascular guanylyl cyclase by endothelial nitric oxide-dependent posttranslational modification. Basic Res Cardiol 2011; 106:539-549.
53. Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011; 123:2132-2144.
54. Münzel T, Harrison DG. Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J Mol Med 1997; 75:891-900.
55. Warnholtz A, Tsilimingas N, Wendt M, Münzel T. Mechanisms underlying nitrate-induced endothelial dysfunction: insight from experimental and clinical studies. Heart Fail Rev 2002; 7:335-345.
56. Daiber A, Münzel T, Gori T. Organic nitrates and nitrate tolerance: state of the art and future developments. Adv Pharmacol 2010; 60:177-227.
57. Liuni A, Luca MC, Di Stolfo G, et al. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. J Am Coll Cardiol 2011; 57:93-98.
58. Knorr M, Hausding M, Kröller-Schuhmacher S, et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol 2011; 31:2223-2231.
59. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370:1483- 1493.
60. Lisi M, Oelze M, Dragoni S, et al. Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates. Clin Res Cardil 2012; 101:453-459.
61. Münzel T, Gori T. Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr Opin Pharmacol 2013; [Epub ahead of print] doi:pii:S1471-4892(13)00004-0. 10.1016/j.coph.2012.12.008.
62. Angeli A. Gazz Chim Ital 1896;26:17.
63. Ferroni E. 'Le Scienze Chimiche' in 'Storia dell'Ateneo Fiorentino', 1989. Firenze: Ed. F. & F. Parretti Grafiche; 1989; 625.
64. Wink DA, Miranda KM, Katori T, et al. Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. Am J Physiol Heart Circ Physiol 2003; 285:H2264-H2276.
65. Fukuto JM, Chiang K, Hszieh R, Wong P, Chaudhuri G. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 1992; 263:546-551.
66. Pino RZ, Feelisch M. Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine. Biochem Biophys Res Commun 1994; 201:54-62.
67. Paolocci N, Katori T, Champion HC, et al. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A 2003; 100:5537-5542.
68. Gao WD, Murray CI, Tian Y, et al. Nitroxyl(HNO)-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res 2012; 111:1002-1011.
69. Ding W, Li Z, Shen X, et al. Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca2. J Pharmacol Exp Ther 2011; 339:825-831.
70. Tocchetti CG, Stanley BA, Murray CI, et al. Playing with cardiac 'redox switches': the 'HNO way' to modulate cardiac function. Antioxid Redox Signal 2011; 14:1687-1698.
71. Paolocci N, Wink DA. The shy Angeli and his elusive creature: the HNO route to vasodilation. Am J Physiol Heart Circ Physiol 2009; 296:H1217- H1220.
72. Paolocci N, Saavedra WF, Miranda KM, et al. Nitroxyl anion exerts redoxsensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci U S A 2011; 98:10463-10468.
73. Favaloro JL, Kemp-Harper BK. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 2007; 73:587-596.
74. Bell D, McDermott BJ. Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol Rev 1996; 48:253-288.
75. Bermejo E, Saenz DA, Alberto F, Rosenstein RE, Bari SE, Lazzari MA. Effect of nitroxyl on human platelets function. Thromb Haemost 2005; 94:578-584.